A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA)

BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory arthritis, with significant impact on quality of life and functional status. Whilst biologic disease modifying anti-rheumatic drugs (bDMARD) such as tumour necrosis factor-inhibitor (TNFi) agents have revolutionised outcomes in RA, earl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Musculoskelet Disord
Autors principals: Dumitru, Raluca B., Horton, Sarah, Hodgson, Richard, Wakefield, Richard J., Hensor, Elizabeth M. A., Emery, Paul, Buch, Maya H.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Study Protocol
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4743173/
https://ncbi.nlm.nih.gov/pubmed/26847108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12891-016-0915-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars